Home/Filings/4/0000882104-16-000099
4//SEC Filing

PDL BIOPHARMA, INC. 4

Accession 0000882104-16-000099

CIK 0000882104operating

Filed

Jan 27, 7:00 PM ET

Accepted

Jan 28, 6:54 PM ET

Size

4.9 KB

Accession

0000882104-16-000099

Insider Transaction Report

Form 4
Period: 2016-01-26
Stone Christopher Lewis
VP and General Counsel
Transactions
  • Award

    Common stock

    2016-01-26$3.22/sh+101,860$327,989236,309 total
Footnotes (1)
  • [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved,based upon the following schedule: 50% on December 2017; 16.66% on December 2018; 16.66% on December 2019; and 16.66% on December 2020.

Issuer

PDL BIOPHARMA, INC.

CIK 0000882104

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000882104

Filing Metadata

Form type
4
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 6:54 PM ET
Size
4.9 KB